Shield Therapeutics plc (LON:STX) Insider Purchases £23,000 in Stock

Shield Therapeutics plc (LON:STX) insider Anders Lundstrom acquired 575,000 shares of the business’s stock in a transaction dated Thursday, February 13th. The stock was acquired at an average price of GBX 4 ($0.05) per share, with a total value of £23,000 ($28,905.37).

Shield Therapeutics Price Performance

Shield Therapeutics stock opened at GBX 3.80 ($0.05) on Friday. The stock has a market capitalization of £37.50 million, a P/E ratio of -0.98 and a beta of 1.42. The company’s fifty day moving average price is GBX 2.76 and its 200 day moving average price is GBX 3.37. The company has a debt-to-equity ratio of 3,691.50, a quick ratio of 2.16 and a current ratio of 1.05. Shield Therapeutics plc has a 1 year low of GBX 1.06 ($0.01) and a 1 year high of GBX 5.95 ($0.07).

Shield Therapeutics Company Profile

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.